Netherlands Liver Diseases Therapeutics Market Report 2022 to 2030

Netherlands Liver Diseases Therapeutics Market Analysis

$ 3999

By 2030, it is anticipated that the Netherlands liver disease therapeutics market will reach a value of $97 Mn from $60 Mn in 2022, growing at a CAGR of 6.2 % during 2022-2030. Liver disease therapeutics in the Netherlands is dominated by a few domestic pharmaceutical companies such as Astellas Pharma, Philips Healthcare, and Pharming Group. The liver disease therapeutics market in the Netherlands is segmented into different types of disease and different therapy types. Some of the major factors affecting the market are the growing prevalence of liver diseases and unhealthy and dynamic lifestyles.

ID: IN10NLPH040 CATEGORY: Pharmaceuticals GEOGRAPHY: Netherlands AUTHOR: Dr. Vishwa Modhia

Buy Now

Netherlands Liver Disease Therapeutics Analysis Summary

By 2030, it is anticipated that the Netherlands liver disease therapeutics market will reach a value of $97 Mn from $60 Mn in 2022, growing at a CAGR of 6.2 % during 2022-30.

The Netherlands is a high-income, developed constituent country located in Western Europe and with territories in the Caribbean. The Dutch liver disease industry is supported by a strong research infrastructure that includes academic medical institutes and biotech businesses. In addition, industrial and academic researchers are working together to create new medicines and diagnostics for the condition.

According to the latest WHO data published in 2020 liver disease deaths in the Netherlands reached 936 or 0.74% of total deaths. The age-adjusted death rate is 3.02 per 100,000 of the population ranking the Netherlands 174^th in the world. Netherlands' government spent 11.1 % of its GDP on healthcare in 2020.

netherlands liver disease therapeutics market analysis

Market Dynamics

Market Growth Drivers

The prevalence of the liver disease is rising in the Netherlands, owing to rising rates of obesity, diabetes, and viral hepatitis. As a result, there is an increasing demand for effective treatments for the disease. To address the issue of liver disease, the Dutch government has implemented a variety of measures, including promoting healthy lifestyles, offering hepatitis B vaccinations to at-risk populations, and enhancing access to liver transplants for individuals with advanced liver disease. Rotterdam, the Netherlands' leading port, facilitates business transactions. The Netherlands' superior infrastructure and living standards are a bonus.

Market Restraints

In the Netherlands, the liver disease industry is becoming increasingly consolidated, with a few large pharmaceutical companies dominating the market. This may provide difficulties for smaller biotech firms seeking to join the market with innovative treatments. The Dutch pension system is under strain as the population ages. These factors may deter new entrants into the Netherlands liver disease therapeutics market.

Competitive Landscape

Key Players

Astellas Pharma: Astellas Pharma is a Japanese pharmaceutical company with a significant presence in the Netherlands. The company produces a range of therapeutics, including those for liver disease. Its liver disease products include Tacrolimus, which is used to prevent liver transplant rejection.
Philips Healthcare: Philips Healthcare is a Dutch company that produces a variety of medical equipment, including those used in liver disease diagnosis and treatment
Merck Sharp & Dohme (MSD): MSD is a multinational pharmaceutical company with a significant presence in the Netherlands. The company produces a range of therapeutics, including those for liver disease. Its liver disease products include Victrelis (boceprevir), a medication used to treat chronic hepatitis C virus (HCV) infection
Pharming Group: Pharming Group is a Dutch biotechnology company that produces a range of therapeutics, including those for liver disease. Its liver disease products include Ruconest (recombinant human C1 esterase inhibitor), which is used to treat hereditary angioedema (HAE) attacks

Healthcare Policies and Reimbursement Scenarios

The Dutch Medicines Evaluation Board (MEB) oversees the regulation of liver disease therapies in the Netherlands. The MEB is responsible for ensuring that all pharmaceutical products, including liver disease therapeutics, fulfill safety, effectiveness, and quality criteria. Liver disease therapies must be registered with the MEB before they may be used in the Netherlands, and producers must follow Good Manufacturing Practices (GMP) and other regulatory requirements. In terms of reimbursement, private health insurance firms in the Netherlands provide minimal health insurance, but they are obligated by law to cover a defined package of medical care, which includes treatments for liver disease.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Netherlands Liver Disease Therapeutics Segmentation

By Treatment Type (Revenue, USD Billion):

Chemotherapy
Antiviral Drugs
Vaccines
Immunosuppressants
Corticosteroids
Immunoglobulins
Targeted Therapy

By Disease Type (Revenue, USD Billion):

Non-alcoholic Fatty Liver Disease (NAFLD)
Autoimmune Diseases
Cancer
Hepatitis
Genetic Disorder
Others

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.